Treatment of Cerebral Meningioma in WHO Grade 2 (Atypical) Meningioma

Clinical Scenario

This protocol addresses cerebral meningioma classified as WHO grade 2 (atypical) — a histologically defined subgroup that carries distinct management requirements.

Specific Situation

WHO Grade 2 · Atypical

In meningioma WHO grade 2, therapy is mandatory. The atypical classification is the central determinant of the treatment pathway selected for this scenario.

Treatment Approach (partial overview)

When no further local treatment option is available, a systemic salvage pharmacotherapy approach targeting specific vascular growth pathways may be considered. The complete regimen, full eligibility criteria, and decision algorithm are in the structured protocol below ↓

Instant Access to Structured Evidence-Based Regimens

References

In meningioma WHO grade 2, therapy is mandatory.

Pharmacotherapy using bevacizumab or multikinase inhibitors targeting VEGF receptors should only be considered if no further local treatment option exists.

DOI: 10.1093/neuonc/noab150

View source ↗